Alnylam announces departure of EVP, Chief Legal Officer Indrani Franchini

ALNYLAM PHARMACEUTICALS, INC.

Separation effective March 1, 2024; severance of $597,000 (12 months' base salary) paid bi-weekly.
Lump sum payment for 2023 annual incentive plan bonus, adjusted by corporate multiplier determined by Board.
One-year consulting arrangement through March 2025; continued vesting of unvested equity awards during consulting period.
$500/hour compensation for consulting beyond 10 hours per month; up to $15,000 legal fee reimbursement.
Consulting period; outstanding stock options remain exercisable for 3 months after consulting period; non-compete restrictions waived.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Indrani L. Franchini

Executive Vice President, Chief Legal Officer and Secretary

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2024-03-01
Filed: March 4, 2024, 6:59 PM ET

Indrani L. Franchini agreed that she would transition from her role as the Company’s Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Indrani L. Franchini changed role as Executive Vice President, Chief Legal Officer and Secretary at ALNYLAM PHARMACEUTICALS, INC..

Action: transitioned
Role: Executive Vice President, Chief Legal Officer and Secretary

Exact text from the filing

Indrani L. Franchini agreed that she would transition from her role as the Company’s Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-057906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.